Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890968838> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W2890968838 endingPage "TPS5613" @default.
- W2890968838 startingPage "TPS5613" @default.
- W2890968838 abstract "TPS5613 Background: Patients with medium and high-risk stage I and II endometrial cancers (EC) have, despite radical surgery, a high risk for progression. Adjuvant brachytherapy or EBRT is the traditional therapy for many decades although without impacting on survival. Several studies have failed to demonstrate superiority of adjuvant chemotherapy in unselected population with a high number of low-risk patients. It is of utmost importance to demonstrate efficacy of adjuvant combination chemotherapy in a randomized trial comparing to no further treatment in the medium and high-risk node negative stage I and stage II patients. Methods: The primary objective of this trial is to evaluate the effect on overall survival of carboplatin-paclitaxel combination chemotherapy against no further systemic treatment. Key eligibility criteria include: histologically confirmed EC, stage I grade 3 endometrioid adenocarcinoma or stage II endometrioid adenocarcinoma or stage I and II type 2 histology (clear cell, serous, squamous cell carcinoma, carcinosarcoma or undifferentiated carcinoma); prior surgery with pelvic lymphadenectomy or sentinel lymph node biopsy. Patients may receive vaginal brachytherapy in both arms. 240 patients are randomized to receive six courses of adjuvant carboplatin (AUC5) and paclitaxel (175mg/m2) combination on day one every 21 days or no further treatment (1:1 randomization). Primary endpoint is overall survival of endometrioid subgroup. Secondary endpoints include overall survival of whole study population, disease specific survival, progression-free survival, toxicity, compliance, Quality of Life (assessed via EORTC QLQ-C30 and EORTC QLQ-EN24), rate of isolated pelvic or distant relapses, as well as mixed relapses. Trial is enrolling patients. The following cooperative groups are participating: DGCG (DK), NSGO (DK, FIN, SWE), BGOG (BEL), MaNGO (ITA), MITO (ITA), GEICO (SPA), NOGGO (GER), CEEGOG (Czech), ISGO (ISR) & MDACC (USA). Clinical trial information: NCT01244789." @default.
- W2890968838 created "2018-09-27" @default.
- W2890968838 creator A5002555374 @default.
- W2890968838 creator A5004691735 @default.
- W2890968838 creator A5005455563 @default.
- W2890968838 creator A5015007361 @default.
- W2890968838 creator A5020292607 @default.
- W2890968838 creator A5023783658 @default.
- W2890968838 creator A5029127743 @default.
- W2890968838 creator A5033251451 @default.
- W2890968838 creator A5039081278 @default.
- W2890968838 creator A5044666878 @default.
- W2890968838 creator A5045683633 @default.
- W2890968838 creator A5073232598 @default.
- W2890968838 creator A5079485962 @default.
- W2890968838 creator A5090491821 @default.
- W2890968838 creator A5091569816 @default.
- W2890968838 date "2017-05-20" @default.
- W2890968838 modified "2023-10-01" @default.
- W2890968838 title "Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer: The ENGOT-EN2/DGCG trial." @default.
- W2890968838 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps5613" @default.
- W2890968838 hasPublicationYear "2017" @default.
- W2890968838 type Work @default.
- W2890968838 sameAs 2890968838 @default.
- W2890968838 citedByCount "4" @default.
- W2890968838 countsByYear W28909688382019 @default.
- W2890968838 countsByYear W28909688382020 @default.
- W2890968838 countsByYear W28909688382022 @default.
- W2890968838 crossrefType "journal-article" @default.
- W2890968838 hasAuthorship W2890968838A5002555374 @default.
- W2890968838 hasAuthorship W2890968838A5004691735 @default.
- W2890968838 hasAuthorship W2890968838A5005455563 @default.
- W2890968838 hasAuthorship W2890968838A5015007361 @default.
- W2890968838 hasAuthorship W2890968838A5020292607 @default.
- W2890968838 hasAuthorship W2890968838A5023783658 @default.
- W2890968838 hasAuthorship W2890968838A5029127743 @default.
- W2890968838 hasAuthorship W2890968838A5033251451 @default.
- W2890968838 hasAuthorship W2890968838A5039081278 @default.
- W2890968838 hasAuthorship W2890968838A5044666878 @default.
- W2890968838 hasAuthorship W2890968838A5045683633 @default.
- W2890968838 hasAuthorship W2890968838A5073232598 @default.
- W2890968838 hasAuthorship W2890968838A5079485962 @default.
- W2890968838 hasAuthorship W2890968838A5090491821 @default.
- W2890968838 hasAuthorship W2890968838A5091569816 @default.
- W2890968838 hasConcept C121608353 @default.
- W2890968838 hasConcept C126322002 @default.
- W2890968838 hasConcept C141071460 @default.
- W2890968838 hasConcept C143998085 @default.
- W2890968838 hasConcept C168563851 @default.
- W2890968838 hasConcept C203092338 @default.
- W2890968838 hasConcept C2776694085 @default.
- W2890968838 hasConcept C2777088508 @default.
- W2890968838 hasConcept C2778239845 @default.
- W2890968838 hasConcept C2780824555 @default.
- W2890968838 hasConcept C2781451048 @default.
- W2890968838 hasConcept C2908647359 @default.
- W2890968838 hasConcept C71924100 @default.
- W2890968838 hasConcept C99454951 @default.
- W2890968838 hasConceptScore W2890968838C121608353 @default.
- W2890968838 hasConceptScore W2890968838C126322002 @default.
- W2890968838 hasConceptScore W2890968838C141071460 @default.
- W2890968838 hasConceptScore W2890968838C143998085 @default.
- W2890968838 hasConceptScore W2890968838C168563851 @default.
- W2890968838 hasConceptScore W2890968838C203092338 @default.
- W2890968838 hasConceptScore W2890968838C2776694085 @default.
- W2890968838 hasConceptScore W2890968838C2777088508 @default.
- W2890968838 hasConceptScore W2890968838C2778239845 @default.
- W2890968838 hasConceptScore W2890968838C2780824555 @default.
- W2890968838 hasConceptScore W2890968838C2781451048 @default.
- W2890968838 hasConceptScore W2890968838C2908647359 @default.
- W2890968838 hasConceptScore W2890968838C71924100 @default.
- W2890968838 hasConceptScore W2890968838C99454951 @default.
- W2890968838 hasIssue "15_suppl" @default.
- W2890968838 hasLocation W28909688381 @default.
- W2890968838 hasOpenAccess W2890968838 @default.
- W2890968838 hasPrimaryLocation W28909688381 @default.
- W2890968838 hasRelatedWork W1503759092 @default.
- W2890968838 hasRelatedWork W1896822451 @default.
- W2890968838 hasRelatedWork W2006385338 @default.
- W2890968838 hasRelatedWork W2027569686 @default.
- W2890968838 hasRelatedWork W2053644560 @default.
- W2890968838 hasRelatedWork W2053778437 @default.
- W2890968838 hasRelatedWork W2060767396 @default.
- W2890968838 hasRelatedWork W2072767112 @default.
- W2890968838 hasRelatedWork W2105623825 @default.
- W2890968838 hasRelatedWork W2220360384 @default.
- W2890968838 hasVolume "35" @default.
- W2890968838 isParatext "false" @default.
- W2890968838 isRetracted "false" @default.
- W2890968838 magId "2890968838" @default.
- W2890968838 workType "article" @default.